Cargando…
Multiomics Analysis of Plasma Proteomics and Metabolomics of Steroid Resistance in Childhood Nephrotic Syndrome Using a “Patient-Specific” Approach
INTRODUCTION: Nephrotic syndrome (NS) occurs commonly in children with glomerular disease and glucocorticoids (GCs) are the mainstay treatment. Steroid resistant NS (SRNS) develops in 15% to 20% of children, increasing the risk of chronic kidney disease compared to steroid sensitive NS (SSNS). NS pa...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239920/ https://www.ncbi.nlm.nih.gov/pubmed/37284673 http://dx.doi.org/10.1016/j.ekir.2023.03.015 |
_version_ | 1785053602910306304 |
---|---|
author | Bhayana, Sagar Zhao, Yue Merchant, Michael Cummins, Timothy Dougherty, Julie A. Kamigaki, Yu Pathmasiri, Wimal McRitchie, Susan Mariani, Laura H. Sumner, Susan Klein, Jon B. Li, Lang Smoyer, William E. |
author_facet | Bhayana, Sagar Zhao, Yue Merchant, Michael Cummins, Timothy Dougherty, Julie A. Kamigaki, Yu Pathmasiri, Wimal McRitchie, Susan Mariani, Laura H. Sumner, Susan Klein, Jon B. Li, Lang Smoyer, William E. |
author_sort | Bhayana, Sagar |
collection | PubMed |
description | INTRODUCTION: Nephrotic syndrome (NS) occurs commonly in children with glomerular disease and glucocorticoids (GCs) are the mainstay treatment. Steroid resistant NS (SRNS) develops in 15% to 20% of children, increasing the risk of chronic kidney disease compared to steroid sensitive NS (SSNS). NS pathogenesis is unclear in most children, and no biomarkers exist that predict the development of pediatric SRNS. METHODS: We studied a unique patient cohort with plasma specimens collected before GC treatment, yielding a disease-only sample not confounded by steroid-induced gene expression changes (SSNS n = 8; SRNS n = 7). A novel “patient-specific” bioinformatic approach merged paired pretreatment and posttreatment proteomic and metabolomic data and identified candidate SRNS biomarkers and altered molecular pathways in SRNS versus SSNS. RESULTS: Joint pathway analyses revealed perturbations in nicotinate or nicotinamide and butanoate metabolic pathways in patients with SRNS. Patients with SSNS had perturbations of lysine degradation, mucin type O-glycan biosynthesis, and glycolysis or gluconeogenesis pathways. Molecular analyses revealed frequent alteration of molecules within these pathways that had not been observed by separate proteomic and metabolomic studies. We observed upregulation of NAMPT, NMNAT1, and SETMAR in patients with SRNS, in contrast to upregulation of ALDH1B1, ACAT1, AASS, ENPP1, and pyruvate in patients with SSNS. Pyruvate regulation was the change seen in our previous analysis; all other targets were novel. Immunoblotting confirmed increased NAMPT expression in SRNS and increased ALDH1B1 and ACAT1 expression in SSNS, following GC treatment. CONCLUSION: These studies confirmed that a novel “patient-specific” bioinformatic approach can integrate disparate omics datasets and identify candidate SRNS biomarkers not observed by separate proteomic or metabolomic analysis. |
format | Online Article Text |
id | pubmed-10239920 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-102399202023-06-06 Multiomics Analysis of Plasma Proteomics and Metabolomics of Steroid Resistance in Childhood Nephrotic Syndrome Using a “Patient-Specific” Approach Bhayana, Sagar Zhao, Yue Merchant, Michael Cummins, Timothy Dougherty, Julie A. Kamigaki, Yu Pathmasiri, Wimal McRitchie, Susan Mariani, Laura H. Sumner, Susan Klein, Jon B. Li, Lang Smoyer, William E. Kidney Int Rep Translational Research INTRODUCTION: Nephrotic syndrome (NS) occurs commonly in children with glomerular disease and glucocorticoids (GCs) are the mainstay treatment. Steroid resistant NS (SRNS) develops in 15% to 20% of children, increasing the risk of chronic kidney disease compared to steroid sensitive NS (SSNS). NS pathogenesis is unclear in most children, and no biomarkers exist that predict the development of pediatric SRNS. METHODS: We studied a unique patient cohort with plasma specimens collected before GC treatment, yielding a disease-only sample not confounded by steroid-induced gene expression changes (SSNS n = 8; SRNS n = 7). A novel “patient-specific” bioinformatic approach merged paired pretreatment and posttreatment proteomic and metabolomic data and identified candidate SRNS biomarkers and altered molecular pathways in SRNS versus SSNS. RESULTS: Joint pathway analyses revealed perturbations in nicotinate or nicotinamide and butanoate metabolic pathways in patients with SRNS. Patients with SSNS had perturbations of lysine degradation, mucin type O-glycan biosynthesis, and glycolysis or gluconeogenesis pathways. Molecular analyses revealed frequent alteration of molecules within these pathways that had not been observed by separate proteomic and metabolomic studies. We observed upregulation of NAMPT, NMNAT1, and SETMAR in patients with SRNS, in contrast to upregulation of ALDH1B1, ACAT1, AASS, ENPP1, and pyruvate in patients with SSNS. Pyruvate regulation was the change seen in our previous analysis; all other targets were novel. Immunoblotting confirmed increased NAMPT expression in SRNS and increased ALDH1B1 and ACAT1 expression in SSNS, following GC treatment. CONCLUSION: These studies confirmed that a novel “patient-specific” bioinformatic approach can integrate disparate omics datasets and identify candidate SRNS biomarkers not observed by separate proteomic or metabolomic analysis. Elsevier 2023-03-23 /pmc/articles/PMC10239920/ /pubmed/37284673 http://dx.doi.org/10.1016/j.ekir.2023.03.015 Text en © 2023 International Society of Nephrology. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Translational Research Bhayana, Sagar Zhao, Yue Merchant, Michael Cummins, Timothy Dougherty, Julie A. Kamigaki, Yu Pathmasiri, Wimal McRitchie, Susan Mariani, Laura H. Sumner, Susan Klein, Jon B. Li, Lang Smoyer, William E. Multiomics Analysis of Plasma Proteomics and Metabolomics of Steroid Resistance in Childhood Nephrotic Syndrome Using a “Patient-Specific” Approach |
title | Multiomics Analysis of Plasma Proteomics and Metabolomics of Steroid Resistance in Childhood Nephrotic Syndrome Using a “Patient-Specific” Approach |
title_full | Multiomics Analysis of Plasma Proteomics and Metabolomics of Steroid Resistance in Childhood Nephrotic Syndrome Using a “Patient-Specific” Approach |
title_fullStr | Multiomics Analysis of Plasma Proteomics and Metabolomics of Steroid Resistance in Childhood Nephrotic Syndrome Using a “Patient-Specific” Approach |
title_full_unstemmed | Multiomics Analysis of Plasma Proteomics and Metabolomics of Steroid Resistance in Childhood Nephrotic Syndrome Using a “Patient-Specific” Approach |
title_short | Multiomics Analysis of Plasma Proteomics and Metabolomics of Steroid Resistance in Childhood Nephrotic Syndrome Using a “Patient-Specific” Approach |
title_sort | multiomics analysis of plasma proteomics and metabolomics of steroid resistance in childhood nephrotic syndrome using a “patient-specific” approach |
topic | Translational Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239920/ https://www.ncbi.nlm.nih.gov/pubmed/37284673 http://dx.doi.org/10.1016/j.ekir.2023.03.015 |
work_keys_str_mv | AT bhayanasagar multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach AT zhaoyue multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach AT merchantmichael multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach AT cumminstimothy multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach AT doughertyjuliea multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach AT kamigakiyu multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach AT pathmasiriwimal multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach AT mcritchiesusan multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach AT marianilaurah multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach AT sumnersusan multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach AT kleinjonb multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach AT lilang multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach AT smoyerwilliame multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach AT multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach |